300653 正海生物
已收盘 03-05 15:00:00
资讯
新帖
简况
正海生物(300653)披露持股5%以上股东减持股份预披露公告,3月2日股价下跌4.1%
证券之星 · 03-02
正海生物(300653)披露持股5%以上股东减持股份预披露公告,3月2日股价下跌4.1%
正海生物披露:隆沃生物拟于3月23日至6月22日期间减持不超过2%公司股份
美股速递 · 02-27
正海生物披露:隆沃生物拟于3月23日至6月22日期间减持不超过2%公司股份
正海生物最新公告:股东Longwood拟减持不超过2%股份
证券之星 · 02-27
正海生物最新公告:股东Longwood拟减持不超过2%股份
股市必读:正海生物(300653)2月13日董秘有最新回复
证券之星 · 02-24
股市必读:正海生物(300653)2月13日董秘有最新回复
正海生物:公司会结合实际经营情况及长期发展战略,综合考量并购重组投资事宜
证券之星 · 02-11
正海生物:公司会结合实际经营情况及长期发展战略,综合考量并购重组投资事宜
股市必读:正海生物(300653)2月5日董秘有最新回复
证券之星 · 02-06
股市必读:正海生物(300653)2月5日董秘有最新回复
正海生物:上年度公司活性生物骨产品的推广入院工作总体有序开展
证券之星 · 02-05
正海生物:上年度公司活性生物骨产品的推广入院工作总体有序开展
股市必读:正海生物(300653)1月29日董秘有最新回复
证券之星 · 01-30
股市必读:正海生物(300653)1月29日董秘有最新回复
正海生物:钙硅生物陶瓷口腔骨修复材料已布局推广策略
证券之星 · 01-16
正海生物:钙硅生物陶瓷口腔骨修复材料已布局推广策略
正海生物(300653.SZ)取得一项医疗器械注册证
智通财经 · 01-09
正海生物(300653.SZ)取得一项医疗器械注册证
宜明昂科与Axion“分手”;江西省卫健委党组书记被查
21世纪经济报道 · 01-08
宜明昂科与Axion“分手”;江西省卫健委党组书记被查
正海生物(300653)披露获得宫腔修复膜医疗器械注册申请《受理通知书》,1月7日股价下跌1.0%
证券之星 · 01-07
正海生物(300653)披露获得宫腔修复膜医疗器械注册申请《受理通知书》,1月7日股价下跌1.0%
正海生物(300653.SZ)一项医疗器械注册申请获受理
智通财经 · 01-07
正海生物(300653.SZ)一项医疗器械注册申请获受理
正海生物:积极探索开发二代活性生物骨产品
证券之星 · 01-05
正海生物:积极探索开发二代活性生物骨产品
正海生物(300653)披露使用闲置自有资金进行现金管理的进展公告,1月5日股价上涨5.61%
证券之星 · 01-05
正海生物(300653)披露使用闲置自有资金进行现金管理的进展公告,1月5日股价上涨5.61%
正海生物:钙硅生物陶瓷骨修复材料注册接近尾声
证券之星 · 2025-12-24
正海生物:钙硅生物陶瓷骨修复材料注册接近尾声
正海生物:重组蛋白项目正稳步推进
证券之星 · 2025-12-16
正海生物:重组蛋白项目正稳步推进
正海生物(300653)披露签订重组III型胶原蛋白技术开发合同,12月15日股价上涨0.24%
证券之星 · 2025-12-15
正海生物(300653)披露签订重组III型胶原蛋白技术开发合同,12月15日股价上涨0.24%
正海生物(300653.SZ)与中国农科院生物所签署一项技术开发合同
智通财经 · 2025-12-15
正海生物(300653.SZ)与中国农科院生物所签署一项技术开发合同
正海生物(300653)披露取得医疗器械注册变更文件,12月09日股价下跌1.4%
证券之星 · 2025-12-09
正海生物(300653)披露取得医疗器械注册变更文件,12月09日股价下跌1.4%
公司概况
公司名称:
烟台正海生物科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2017-05-16
主营业务:
烟台正海生物科技股份有限公司的主营业务是生物再生材料的研发、生产与销售。公司的主要产品是口腔修复膜、可吸收硬脑(脊)膜补片、硬脑(脊)膜补片、皮肤修复膜、骨修复材料、活性生物骨、光固化复合树脂、自酸蚀粘接剂、窝沟封闭剂、磷酸酸试剂、外科用填塞海绵。公司历经20余年的发展,先后承担了国家“863计划”、国家火炬计划,是国家首批专精特新“小巨人”企业、国家知识产权示范企业、高新技术企业。
发行价格:
11.72
{"stockData":{"symbol":"300653","market":"SZ","secType":"STK","nameCN":"正海生物","latestPrice":19.66,"timestamp":1772694198000,"preClose":19.61,"halted":0,"volume":1410775,"delay":0,"changeRate":0.0025,"floatShares":180000000,"shares":180000000,"eps":0.4277,"marketStatus":"已收盘","change":0.05,"latestTime":"03-05 15:00:00","open":19.82,"high":19.91,"low":19.57,"amount":27839700,"amplitude":0.0173,"askPrice":19.7,"askSize":1,"bidPrice":19.66,"bidSize":10,"shortable":0,"etf":0,"ttmEps":0.4277,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772760600000},"marketStatusCode":5,"adr":0,"adjPreClose":19.61,"symbolType":"stock","openAndCloseTimeList":[[1772674200000,1772681400000],[1772686800000,1772694000000]],"highLimit":21.57,"lowLimit":17.65,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":180000000,"isCdr":false,"pbRate":4.04,"roa":"--","peRate":45.966799,"roe":"7.61%","epsLYR":0.75,"committee":0.340206,"marketValue":3539000000,"turnoverRate":0.0078,"status":0,"floatMarketCap":3539000000},"requestUrl":"/m/hq/s/300653/wiki","defaultTab":"wiki","newsList":[{"id":"2616660380","title":"正海生物(300653)披露持股5%以上股东减持股份预披露公告,3月2日股价下跌4.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616660380","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616660380?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:44","pubTimestamp":1772444643,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,正海生物报收于20.11元,较前一交易日下跌4.1%,最新总市值为36.2亿元。该股当日开盘20.5元,最高20.65元,最低20.02元,成交额达7590.74万元,换手率为2.08%。近日,正海生物发布《关于持股5%以上股东减持股份的预披露公告》。减持期间为2026年3月23日至2026年6月22日,价格将根据市场情况确定。Longwood已履行此前各项承诺,本次减持计划符合相关法规规定,不会对公司治理结构和持续经营产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200026600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300653","BK0046"],"gpt_icon":0},{"id":"1170020464","title":"正海生物披露:隆沃生物拟于3月23日至6月22日期间减持不超过2%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1170020464","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170020464?lang=zh_cn&edition=full","pubTime":"2026-02-27 19:01","pubTimestamp":1772190095,"startTime":"0","endTime":"0","summary":"正海生物发布公告称,其股东隆沃生物技术有限公司计划在2024年3月23日至6月22日期间,通过集中竞价或大宗交易方式减持公司股份,减持比例不超过公司总股本的2%。此次减持计划将根据市场情况、公司股价等因素择机实施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300653","BK0046","BK0251"],"gpt_icon":0},{"id":"2614834425","title":"正海生物最新公告:股东Longwood拟减持不超过2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2614834425","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614834425?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:40","pubTimestamp":1772188805,"startTime":"0","endTime":"0","summary":"正海生物(300653.SZ)公告称,持股5%以上股东Longwood Biotechnologies Inc.计划自公告披露之日起15个交易日后的3个月内(即2026年3月23日至2026年6月22日),以集中竞价交易或大宗交易方式合计减持公司股份不超过360万股,占公司总股本比例2%;减持原因为资金需求;股份来源为公司首次公开发行前发行的股份及资本公积金转增股份。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700033952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"gpt_icon":0},{"id":"2613731288","title":"股市必读:正海生物(300653)2月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2613731288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613731288?lang=zh_cn&edition=full","pubTime":"2026-02-24 02:44","pubTimestamp":1771872253,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘,正海生物报收于20.48元,下跌0.24%,换手率0.89%,成交量1.59万手,成交额3281.78万元。如果您是股东,请致电公司投资者热线予以查询:0535-6971993,公司在核实股东身份后予以回复。交易信息汇总资金流向2月13日主力资金净流出223.43万元,占总成交额6.81%;游资资金净流出138.33万元,占总成交额4.21%;散户资金净流入361.76万元,占总成交额11.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400007685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"gpt_icon":0},{"id":"2610937233","title":"正海生物:公司会结合实际经营情况及长期发展战略,综合考量并购重组投资事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2610937233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610937233?lang=zh_cn&edition=full","pubTime":"2026-02-11 20:51","pubTimestamp":1770814274,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)02月10日在投资者关系平台上答复投资者关心的问题。投资者提问:现在市场环境和监管部门支持并购重组,做大做强上市公司,难道贵公司没考虑想关路径?稳健经营很好,但也要适当考虑资本运作,谢谢。正海生物回复:您好!公司实时关注并购重组等方面的政策指引和发展动态,公司会结合实际经营情况及长期发展战略,综合考量并购重组投资事宜。若有相关进展,公司将依法履行相关审议程序并及时进行信息披露。感谢您的关注及建议!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100036192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300653","BK0046","161123"],"gpt_icon":0},{"id":"2609758554","title":"股市必读:正海生物(300653)2月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2609758554","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609758554?lang=zh_cn&edition=full","pubTime":"2026-02-06 02:36","pubTimestamp":1770316575,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘,正海生物报收于20.76元,上涨0.14%,换手率1.3%,成交量2.34万手,成交额4871.11万元。上年度公司活性生物骨产品的推广入院工作总体有序开展,入院节奏及放量符合预期,产品推广应用反馈良好,公司对于产品持续放量保持信心。公司回购股份拟用于员工激励,公司将按相关规则筹划后续员工激励具体实施方案,同时也会按照监管要求及时履行信披义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600001950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"gpt_icon":0},{"id":"2609370648","title":"正海生物:上年度公司活性生物骨产品的推广入院工作总体有序开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2609370648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609370648?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:48","pubTimestamp":1770295714,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)02月05日在投资者关系平台上答复投资者关心的问题。投资者提问:你好 公司25年活性生物骨销售情况符合预期吗 回购的股份什么时候落实用途?正海生物回复:您好!上年度公司活性生物骨产品的推广入院工作总体有序开展,入院节奏及放量符合预期,产品推广应用反馈良好,公司对于产品持续放量保持信心。公司回购股份拟用于员工激励,公司将按相关规则筹划后续员工激励具体实施方案,同时也会按照监管要求及时履行信披义务。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500037511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300653","BK0251"],"gpt_icon":0},{"id":"2607582670","title":"股市必读:正海生物(300653)1月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2607582670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607582670?lang=zh_cn&edition=full","pubTime":"2026-01-30 03:00","pubTimestamp":1769713238,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘,正海生物报收于20.79元,下跌1.42%,换手率1.32%,成交量2.38万手,成交额4994.45万元。董秘最新回复投资者: 请问南京集采降价挂网后,为何有两个型号的活性骨被公司申请了撤网?公司在相关区域调整产品挂网主要考量了该区域产品市场需求及撤网政策等因素。公司将持续推进活性生物骨产品入院及放量工作,不断提升产品营收贡献水平。当日关注点来自交易信息汇总:1月29日主力资金净流出409.23万元,游资资金净流入528.38万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000001685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300653","BK0251"],"gpt_icon":0},{"id":"2603457956","title":"正海生物:钙硅生物陶瓷口腔骨修复材料已布局推广策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2603457956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603457956?lang=zh_cn&edition=full","pubTime":"2026-01-16 11:35","pubTimestamp":1768534502,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物01月16日在投资者关系平台上答复投资者关心的问题。公司在钙硅生物陶瓷口腔骨修复材料上市前就已提前布局产品推广策略,同时在产品转产、品牌宣传搭建等方面提前部署了准备工作,策略充分了结合产品在组分、结构及工艺等方面的创新优势以及产品目标市场的综合情况,将通过差异化营销路线实施产品上市推广,以实现产品盈利水平最大化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600015286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0251","BK0046"],"gpt_icon":0},{"id":"2602032827","title":"正海生物(300653.SZ)取得一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2602032827","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602032827?lang=zh_cn&edition=full","pubTime":"2026-01-09 15:59","pubTimestamp":1767945545,"startTime":"0","endTime":"0","summary":"智通财经APP讯,正海生物(300653.SZ)公告,公司近日取得由国家药品监督管理局下发的《医疗器械注册证》,产品名称为:钙硅生物陶瓷口腔骨修复材料。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0046","BK1222","09997","BK1100","300653","BK0251","BK1583","09996","159883"],"gpt_icon":0},{"id":"2601533894","title":"宜明昂科与Axion“分手”;江西省卫健委党组书记被查","url":"https://stock-news.laohu8.com/highlight/detail?id=2601533894","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601533894?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:41","pubTimestamp":1767832919,"startTime":"0","endTime":"0","summary":"政策动向国家药监局:优化临床急需境外已上市药品审评审批央视新闻消息显示,为加快临床急需境外已上市药品在境内上市,满足患者临床用药迫切需求,国家药监局进一步优化这类药品审评审批。国家药监局表示,坚持以临床价值为导向,鼓励申请人在中国开展全球同步研发、同步申报上市;鼓励临床急需境外已上市的原研药及仿制药在境内申报,对于符合要求的可纳入优先审评审批范围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601083612141760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601083612141760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU1997244956.HKD","LU1255011170.USD","BK0012","BK0114","BK0196","LU1580142542.USD","LU2495084118.USD","LU2097828805.USD","LU1064130708.USD","688759","LU2097828474.EUR","LU2097828714.EUR","LU2289578879.USD","BK0046","BK0188","LU2580892789.USD","LU1820825898.SGD","BK0060","LU1064131003.USD","LU1997245177.USD","BK0251","LU0405327494.USD","LU1655091616.SGD","LU1781817850.SGD","LU1997245094.SGD","LU2097828557.USD","LU1328615791.USD","002173","LU1146622755.USD","LU2328871848.SGD","LU2488822045.USD","BK0183","BK0077","LU2097828631.EUR","BK0028","LU0405327148.USD","600276","BK0236","688321","LU2148510915.USD","LU2580892862.HKD","BK0239","BK0096","300653"],"gpt_icon":0},{"id":"2601801140","title":"正海生物(300653)披露获得宫腔修复膜医疗器械注册申请《受理通知书》,1月7日股价下跌1.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801140","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601801140?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:36","pubTimestamp":1767796577,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘,正海生物报收于20.76元,较前一交易日下跌1.0%,最新总市值为37.37亿元。该股当日开盘20.96元,最高21.0元,最低20.71元,成交额达4939.7万元,换手率为1.32%。该产品尚处于受理阶段,对公司现有业务和经营业绩预计不会产生确定性影响,未来上市及生产存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700039127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK1583","BK1222","BK1574","300653","09996","09997","159883","BK1100","BK0251"],"gpt_icon":0},{"id":"2601789398","title":"正海生物(300653.SZ)一项医疗器械注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601789398","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601789398?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:18","pubTimestamp":1767773912,"startTime":"0","endTime":"0","summary":"智通财经APP讯,正海生物(300653.SZ)公告,公司近日收到国家药品监督管理局下发的医疗器械注册申请《受理通知书》,相关产品名称为:宫腔修复膜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK0251","BK1100","BK0046","300653","BK1222","09997","BK1583","09996","BK1574"],"gpt_icon":0},{"id":"2601894908","title":"正海生物:积极探索开发二代活性生物骨产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894908","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601894908?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:51","pubTimestamp":1767617474,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)01月04日在投资者关系平台上答复投资者关心的问题。投资者提问:据传九源基因注射型骨诱导(含bmp-2的骨修复材料)于26年上半年完成上市注册审批。请问公司有无二代活性骨研发计划?若有则二代产品有何改进?另请公司加速推广销售,市场不等人!正海生物回复:您好!公司将结合骨修复技术和相关市场变化以及公司发展战略,积极探索开发二代活性生物骨产品的可能性及市场前景。感谢您对公司的关注与建议!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500037401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0251","BK0046"],"gpt_icon":0},{"id":"2601007130","title":"正海生物(300653)披露使用闲置自有资金进行现金管理的进展公告,1月5日股价上涨5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601007130","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601007130?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:31","pubTimestamp":1767609098,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘,正海生物报收于21.09元,较前一交易日上涨5.61%,最新总市值为37.96亿元。该股当日开盘19.99元,最高21.33元,最低19.97元,成交额达1.09亿元,换手率为2.91%。公司近日发布公告称,烟台正海生物科技股份有限公司使用闲置自有资金进行现金管理,近期购买多款理财产品,包括中信证券、浦发银行等机构发行的稳健型产品,总金额达38,000万元,部分产品已到期并取得收益。该事项已经董事会、监事会及股东大会审议通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500029153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300653","BK0046"],"gpt_icon":0},{"id":"2593423076","title":"正海生物:钙硅生物陶瓷骨修复材料注册接近尾声","url":"https://stock-news.laohu8.com/highlight/detail?id=2593423076","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593423076?lang=zh_cn&edition=full","pubTime":"2025-12-24 11:37","pubTimestamp":1766547433,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物12月23日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,贵公司原本预计钙硅生物陶瓷骨修复材料预计于2025年内取得注册证,年内能达成吗?公司钙硅生物陶瓷骨修复材料产品注册工作已接近尾声,公司将持续跟进产品注册进展并及时履行信披义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400014660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0251","BK0046"],"gpt_icon":0},{"id":"2591109602","title":"正海生物:重组蛋白项目正稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2591109602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591109602?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:39","pubTimestamp":1765874356,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物12月16日在投资者关系平台上答复投资者关心的问题。公司与江苏集萃研究所合作开展的“重组生物活性蛋白产品的研究开发”项目正稳步推进中,不存在终止合作的情形。两项合作开发项目具有不同的研发方向及技术路径,都是公司为丰富产品矩阵、提升长期竞争力的战略举措。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600025191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0251","300653"],"gpt_icon":0},{"id":"2591642159","title":"正海生物(300653)披露签订重组III型胶原蛋白技术开发合同,12月15日股价上涨0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642159?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:29","pubTimestamp":1765808949,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘,正海生物报收于20.68元,较前一交易日上涨0.24%,最新总市值为37.22亿元。该股当日开盘20.6元,最高20.9元,最低20.24元,成交额达4004万元,换手率为1.08%。公司近日发布公告称,烟台正海生物科技股份有限公司与中国农业科学院生物技术研究所签署关于‘重组III型胶原蛋白产品的研究开发’项目的《技术开发合同》,合同总金额为1,200万元,将按里程碑节点分期支付。项目研究成果及知识产权由双方共有,甲方享有独占使用权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500036019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"gpt_icon":0},{"id":"2591619376","title":"正海生物(300653.SZ)与中国农科院生物所签署一项技术开发合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2591619376","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591619376?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:22","pubTimestamp":1765786939,"startTime":"0","endTime":"0","summary":"智通财经APP讯,正海生物(300653.SZ)公告,公司近日与受托方中国农业科学院生物技术研究所(简称“中国农科院生物所”)签署了关于“重组III型胶原蛋白产品的研究开发”项目的《技术开发合同》。合同总金额为1200万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0251","300653"],"gpt_icon":0},{"id":"2590342820","title":"正海生物(300653)披露取得医疗器械注册变更文件,12月09日股价下跌1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590342820","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590342820?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:21","pubTimestamp":1765290113,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘,正海生物报收于21.1元,较前一交易日下跌1.4%,最新总市值为37.98亿元。该股当日开盘21.37元,最高21.49元,最低21.05元,成交额达6885.58万元,换手率为1.8%。公司于近日发布公告称,烟台正海生物科技股份有限公司于近日取得国家药品监督管理局颁发的《医疗器械变更注册(备案)文件》,完成产品“皮肤修复膜”的规格型号及产品技术要求的变更。上述变更文件需与原注册证共同使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900040821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK0046","BK1574","300653","BK1100","BK1583","09997","BK1222","BK0251","159883"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772749086832,"stockEarnings":[{"period":"1week","weight":-0.0548},{"period":"1month","weight":-0.0498},{"period":"3month","weight":-0.0948},{"period":"6month","weight":-0.0349},{"period":"1year","weight":-0.0801},{"period":"ytd","weight":-0.0155}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台正海生物科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"15878人(较上一季度减少5.57%)","perCapita":"11336股","listingDate":"2017-05-16","address":"山东省烟台市福山区经济技术开发区南京大街7号","registeredCapital":"18000万元","survey":" 烟台正海生物科技股份有限公司的主营业务是生物再生材料的研发、生产与销售。公司的主要产品是口腔修复膜、可吸收硬脑(脊)膜补片、硬脑(脊)膜补片、皮肤修复膜、骨修复材料、活性生物骨、光固化复合树脂、自酸蚀粘接剂、窝沟封闭剂、磷酸酸试剂、外科用填塞海绵。公司历经20余年的发展,先后承担了国家“863计划”、国家火炬计划,是国家首批专精特新“小巨人”企业、国家知识产权示范企业、高新技术企业。","listedPrice":11.72},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"正海生物(300653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供正海生物(300653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"正海生物,300653,正海生物股票,正海生物股票老虎,正海生物股票老虎国际,正海生物行情,正海生物股票行情,正海生物股价,正海生物股市,正海生物股票价格,正海生物股票交易,正海生物股票购买,正海生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"正海生物(300653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供正海生物(300653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}